COMMUNIQUÉS West-GlobeNewswire

Breakthrough in Obesity Solutions: Fuzzle’s Non-Invasive Oral Device Begins FDA Review Process
14/10/2025
Dover, DE, Oct. 14, 2025 (GLOBE NEWSWIRE) -- In a major step forward for obesity solutions, Fuzzle, a pioneering health technology company, announced today that its innovative oral device has officially entered the U.S [...]
Nova Leap Health Corp. to Highlight Record Q2 2025 Results at Planet MicroCap Showcase Toronto
14/10/2025
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Oct. 14, 2025 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a [...]
Spineway : Revenue growth in the third quarter
14/10/2025
Ecully, October 14, 2025 – 6:30 p.m. SPINEWAY Revenue growth in the third quarter In thousands of euros 2025 2024 Change as a % Q3 revenue 3,045 2,575 +18% Q2 revenue 2,745 3,465 -21% Q1 revenue 2,828 3,070 -8% 9M [...]
SPINEWAY : Croissance du chiffre d’affaires au 3ème trimestre
14/10/2025
Ecully, le 14 octobre 2025 – 18h30 SPINEWAY Croissance du chiffre d’affaires au 3ème trimestre En milliers d’euros 2025 2024 Variation en % CA 3 ème trimestre 3 045 2 575 + 18% CA 2 ème trimestre 2 745 3 465 - 21% CA 1 [...]
The Global Myeloma Community Mourns the Passing of IMF Co-Founder Dr. Brian G.M. Durie
14/10/2025
LOS ANGELES, Oct. 14, 2025 (GLOBE NEWSWIRE) -- It is with great sadness that the International Myeloma Foundation (IMF) shares the news of the death of Dr. Brian G.M. Durie, co-founder of the organization. A Media [...]
Sanofi: Information concerning the total number of voting rights and shares - September 2025
14/10/2025
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Septembre 2025
14/10/2025
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]
Turn Therapeutics Appoints Arthur Golden to Board of Directors
14/10/2025
Veteran corporate advisor to strengthen governance, oversight, and strategic execution as the Company advances late-stage programs WESTLAKE VILLAGE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (“Turn” or [...]
Sequana Medical alfapump® System Highlighted at SIR EDGE 2025 Conference
14/10/2025
Ghent, Belgium , Oct. 14, 2025 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA (the “Company” or “Sequana Medical” ), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart [...]
New Peer-Reviewed Study Shows Cylinder’s Digital Digestive Health Program Improves Outcomes for Socially Vulnerable Populations
14/10/2025
CHICAGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cylinder , the leading virtual digestive health provider, today announced results from a new peer-reviewed study published in JMIR Formative Research , which showed that 86% of [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 septembre 2025
14/10/2025
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 septembre 2025 En application de l'article L. 233-8 II du code de commerce et de l'article 222-12-5 du règlement général de l'AMF [...]
Alignment Health Plan and Intermountain Health Launch $0-Premium, 5-star Medicare Advantage Plan for Nevada Seniors
14/10/2025
New co-branded HMO expands access to high-quality, affordable care in Clark County, adding second 5-star plan for Alignment in the state LAS VEGAS, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Alignment Health Plan , an award- [...]
FibroBiologics to Present at the 2025 ThinkEquity Conference
14/10/2025
HOUSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]
Flare Therapeutics to Present FX-909 Phase 1A Data in Oral Presentation at Upcoming AACR-NCI-EORTC International Conference
14/10/2025
CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other [...]
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
14/10/2025
Prestigious European Society for Medical Oncology Conference “trials-in-progress” session Pivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed patients underway Company on track with established [...]
Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides
14/10/2025
First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) subtype, poikilodermatous mycosis fungiodes (pMF), underscoring the Company’s XTRAC capability to [...]
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
14/10/2025
$50 million drawn down at closing, with access to up to an additional $80 million Strengthens Company’s financial position; enables initiation of phase 3 clinical trial of CAN-2409 in non-small cell lung cancer (NSCLC) [...]
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
14/10/2025
NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
14/10/2025
EMERYVILLE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]

Pages